Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 4, 2010

View Archived Issues

CMX-001 is not nephrotoxic in patients with viral infections

Cationic peptide NP-339 is active against Candida species

EP-017796 is active against drug-resistant bacteria

NNC-126-0083 is well tolerated in adults and children with growth hormone deficiency

Phase I investigation of CombiHIVvac HIV vaccine begins

FDA grants type B meeting to Repros to discuss phase III protocols for Androxal

Circassia advances novel T-cell allergy vaccines

Phase II trial of IMA-901 shows benefit of cyclophosphamide pretreatment

Bayer Schering Pharma identifies new activators of soluble guanylate cyclase

Teva and Oncogenex begin second phase III custirsen trial in prostate cancer

Merck Serono claims new inhibitors of PI3K

New inhibitors of C-raf/B-raf identified by Novartis

Data monitoring committee recommends continuation of phase III ThermoDox trial

Aveo Pharmaceuticals regains worldwide rights to AV-299

Repligen completes enrollment in phase IIb RG-2417 trial

Roche claims new inhibitors of NS5B for HCV infections

Banyu and Merck & Co. discover new PKB inhibitors

A&G Pharma receives NCI grant for GP88-directed antibody for breast cancer

Dyax and CMIC partner in development and marketing of DX-88 for HAE in Japan

Valeant Pharma and Biovail complete merger

Keryx advances phase III program for hyperphosphatemia treatment Zerenex

Ablynx begins enrollment in phase II trial of ALX-0081 and ALX-0681 in TTP

Phase III trial of lixisenatide in combination with basal insulin meets primary endpoint

PolyMedix receives phase II NIH grant to develop antimicrobial defensin mimetic

FDA grants fast track status to Emergent's AVP-21D9 anthrax program

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Sun Pharma to acquire Merck spinoff Organon for $11.75B
BioWorld
Sun Pharmaceuticals Industries Ltd. will pay $11.75 billion cash to acquire Organon & Co. The transaction is expected to close in early 2027. The addition of...